Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1) - Result

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Research output: Contribution to journal › Journal article › Research › peer-review

Documents

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1)_(accepted_version)
Accepted author manuscript, 632 KB, PDF document

Eric L Simpson
Rodney Sinclair
Seth Forman
Andreas Wollenberg
Roland Aschoff
Michael Cork
Thomas Bieber
Thyssen, Jacob Pontoppidan
Gil Yosipovitch
Carsten Flohr
Nina Magnolo
Catherine Maari
Claire Feeney
Pinaki Biswas
Svitlana Tatulych
Hernan Valdez
Ricardo Rojo

Original language	English
Journal	The Lancet
Volume	396
Issue number	10246
Pages (from-to)	255-266
Number of pages	12
ISSN	0140-6736
DOIs	https://doi.org/10.1016/S0140-6736(20)30732-7
Publication status	Published - 1 Jul 2020

ID: 260746011